Cambridge Antibody Technology Limited
Records under this name other than patents Cambridge Antibody Technology Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cambridge Antibody Technology Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,829,090 | Human antibody molecules for IL-13 Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,085,628 | Antibody molecule for human GM-CSF receptor alpha Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,518,645 | Method of mutagenesis Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,182,817 | Antibodies to Human IL-22 Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,723,486 | Antibodies to Tgf-Beta Formerly held In force · High confidence | In force | High confidence | |
| US 7,901,684 | Antibodies Against Human IL-22 and Uses Therefor Formerly held In force · High confidence | In force | High confidence | |
| US 8,288,123 | Methods and means relating to protein variants Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,187,603 | Antibodies to Human IL-22 Formerly held In force · High confidence | In force | High confidence | |
| US 8,506,960 | Antibody molecule for human GM-CSF receptor alpha Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,315,575 | Methods of treatment using human antibody molecules for IL-13 Formerly held In force · USPTO record | In force | USPTO record |